Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3417 Results for "
mSWI/SNF complex
" in MedChemExpress (MCE) Product Catalog:
Products (3417)
3417 Results for "mSWI/SNF complex" in MCE Product Catalog:
Cat. No.: HY-183075
CAS No.: 1648720-01-7
Target:
Research Areas:
ND-011458 is an Antibacterial agent, a QcrB inhibitor, and also an inhibitor of cytochrome bcc:aa3 oxidase function. ND-011458 binds to the QcrB subunit of cytochrome bcc:aa3 oxidase. ND-011458 inhibits ATP formation. When used in combination with Clofazimine (HY-B1046), ND-011458 exhibits bactericidal activity against Mycobacterium abscessus. ND-011458 can be used in studies related to Mycobacterium abscessus pulmonary infections .
Cat. No.: HY-186268
CAS No.: 3034180-15-6
Research Areas:
BRD4 ligand-Linker Conjugate 8 is a Target Protein Ligand-Linker Conjugate that can be used in studies related to PROTAC synthesis. BRD4 ligand-Linker Conjugate 8 is applicable for the synthesis of BD-7148 (HY-186267) .
Target:
Research Areas:
BD-9136 is a selective BRD4 PROTAC degrader with a DC50 of 1.2 nM, and exhibits a selectivity of ≥1000-fold over BRD2 and BRD3. BD-9136 preferentially forms a ternary complex with the BD1 domain of BRD4, and downregulates the expression of B7-H4 by disrupting the PR-P300-BRD4 axis. BD-9136 depletes BRD4 protein in tumor tissues, inhibits tumor growth, reduces B7-H4 protein expression, increases CD8+ T cell infiltration, and enhances tumor sensitivity to anti-PD-L1. Degradation of BRD4 by BD-9136 rescues the erythroid differentiation block induced by LSD1 inhibition, and transient administration restores erythroid output while retaining HbF induction. BD-9136 causes no adverse effects in mice at effective doses. BD-9136 can be used in studies related to acute myeloid leukemia, acute lymphoblastic leukemia and breast cancer .
Cat. No.: HY-162775
CAS No.: 50566-97-7
Target:
Research Areas:
TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC50=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (KD=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974) .
Cat. No.: HY-179560
Research Areas:
PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y220C-PLK1 ternary complex (EC50 = 1.4 μM). PMV6-PEG4-BI2536 causes PLK1 mislocalization and inhibits PLK1 activity, inducing G2/M phase arrest and apoptosis in p53 Y220C-mutant cells, while sparing cells with wild-type TP53. PMV6-PEG4-BI2536 can be used in research on uterine, gastric, pancreatic, prostate, and breast cancers harboring the p53 Y220C mutation. PMV6-PEG4-BI2536 is composed of PMV6 (a p53 Y220C mutant-binding ligand), PEG4 (a linker), and BI2536 (HY-159493) (a PLK inhibitor) .
Cat. No.: HY-181413
CAS No.: 3093642-25-9
Research Areas:
PROTAC EZH2 Degrader-44 (compound 60) is a highly efficient PROTAC degrader targeting the EZH2-PRC2 complex. By recruiting the CRBN E3 ligase and relying on the proteasome system, PROTAC EZH2 Degrader-44 simultaneously induces the degradation of core components EZH2, SUZ12 and EED, thereby significantly reducing the levels of H3K27me3 and CARM1. PROTAC EZH2 Degrader-44 exerts antiproliferative effects through a dual mechanism: on the one hand, it triggers mitochondrial dysfunction leading to decreased membrane potential; on the other hand, it strongly promotes apoptosis by regulating Bcl-2 family proteins (upregulating Bax, Caspase-3 and PARP, and downregulating Bcl-2). PROTAC EZH2 Degrader-44 exhibits only extremely low cytotoxicity in human normal mammary epithelial, liver and kidney cells, showing a favorable safety window. PROTAC EZH2 Degrader-44 is an ideal tool molecule for exploring the mechanisms of targeted therapy for triple-negative breast cancer .
Cat. No.: HY-W1143867
CAS No.: 2226-71-3
Research Areas:
4’-Phosphopantetheine is an orally active coenzyme A (CoA) precursor. 4’-Phosphopantetheine is membrane-permeable and acts as a CoA precursor, a prosthetic group, and a reactive oxygen species (ROS) inhibitor. 4’-Phosphopantetheine binds covalently to rat liver fatty acid synthase, modifies the conserved serine residue in the PKS/NRPS carrier protein domain, and serves as a substrate for CoA synthase and PPAT. 4’-Phosphopantetheine undergoes non-catalytic exchange on rat liver fatty acid synthase, with a faster turnover rate than that of the enzyme complex, and restores intracellular CoA levels in cells with impaired de novo biosynthesis. 4’-Phosphopantetheine rescues phenotypes induced by CoA deficiency, normalizes PKAN-related biomarkers, restores mitochondrial enzyme activity, and alleviates vascular endothelial damage. 4’-Phosphopantetheine shows biological stability in serum, acts as a prosthetic group and degradation product of ACP, and inhibits the formation of atherosclerotic plaques. 4’-Phosphopantetheine can be used in the research of brain iron accumulation neurodegenerative diseases, pantothenate kinase-associated neurodegeneration, CoASY protein-associated neurodegenerative diseases, coronary heart disease, and atherosclerosis .
Cat. No.: HY-L246
1,039 compounds
Tonifying traditional Chinese medicines occupy a central position in the traditional medical system, with their core value lying in the regulation of the body's functional state. Modern pharmacological studies have confirmed that these medicinal materials and their monomeric components possess multiple biological activities, including bidirectional immune regulation, anti-aging and lifespan extension, neuroprotection and cognitive enhancement, as well as hematopoietic and metabolic regulation. According to the traditional Chinese medicine theory of “strengthening the body’s resistance and consolidating the foundation”, tonifying medicines are mainly classified into four major categories: Qi-tonifying, Blood-tonifying, Yin-tonifying, and Yang-tonifying. This compound library strictly follows this classification system for compound collection.
Monomeric compounds derived from traditional Chinese medicines demonstrate excellent drug-like properties. They naturally possess structural diversity and clearly defined pharmacological activities, which help improve screening success rates and make them ideal tools for studying multi-target synergistic effects. This library contains 1,039 compounds, providing a material basis for investigating synergistic interactions among compounds (network pharmacology) and facilitating the development of multi-target therapeutic strategies for complex diseases such as cancer, neurodegenerative disorders, and metabolic syndrome.
Cat. No.: HY-P703733
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: BTN2A1; BTN2.1; Butyrophilin Subfamily 2 Member A1; Butyrophilin, Subfamily 2, Member A1; BT2.1; BK14H9.1; BTF1; DJ3E1.1; BTN3A1; CD277; Butyrophilin Subfamily 3 Member A1; DJ45P21.3 (Butyrophilin, Subfamily 3, Member A1); BTF5; Butyrophilin, Subfamily 3,
Species:
Human
Source:
HEK293
Cat. No.: HY-169378
CSI86 is a c-MYC PROTAC degrader. CSI86 inhibits the proliferation of various cancer cells and exhibits excellent cellular uptake capacity. CSI86 maintains stability for 72 h in cell culture medium. CSI86 can be used in studies related to breast cancer and prostate cancer .
Cat. No.: HY-187200
Target:
Research Areas:
SP-393D is an amidoxime-based prodrug inhibitor targeting dengue virus NS2B/NS3. The EC50 values of SP-393D in Huh7 cells infected with DENV-1, DENV-2, DENV-3 and DENV-4 are 1.41, 0.066, 0.66 and 0.071 μM, respectively, while its CC50 against Huh7 cells is >100 μM. SP-393D exhibits pan-serotypic activity against dengue virus serotypes 1, 2, 3 and 4. SP-393D binds to the allosteric pocket of dengue virus NS2B/NS3 protease and generates additional hydrogen bonding interactions. SP-393D can be used in studies related to dengue virus infection .
Cat. No.: HY-P991150
CAS No.: 2981477-39-6
Target:
Research Areas:
Cat. No.: HY-P72368
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal Fragment Crystallizable Fc Receptor FcRn; IgG Fc Fragment Receptor Transporter Alpha Chain; Immunoglobulin Receptor, Intestinal, Heavy Chain; IgG Receptor FcRn Large Subunit P51; Neonatal Fc-Receptor For Ig; FcgammaRn; FCRN Alpha-Chain; Heavy Chain Of The Major Histocompatibility complex Class I-Like Fc Receptor; FcRn Alpha Chain; Transmembrane Alpha Chain Of The Neonatal Receptor; Alpha-Chain; Fc Fragment Of IgG, Receptor, Transporter, Alpha; FCRN; Fc Fragment Of IgG Receptor And Transporter; B2M; Beta 2-Microglobulin; Beta-2-Microglobulin; Beta-2-Microglobin; Beta Chain Of MHC Class I Molecules; AMYLD6; Beta 2-Microglobulin Protein; MHC1D4; Human Nkt Tcr Alpha Chain; IMD43; Human Nkt Tcr Beta Chain
Species:
Human
Source:
HEK293
Cat. No.: HY-P86815
Synonyms: ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; Polyadenylation factor Clp1 antibody; Polynucleotide kinase Clp1 antibody; Polyribonucleotide 5' hydroxyl kinase Clp1 antibody; Polyribonucleotide 5''-hydroxyl-kinase Clp1 antibody; Pre mRNA cleavage complex II protein Clp1 antibody; Pre-mRNA cleavage complex II protein Clp1 antibody;
Cat. No.: HY-P992155
Synonyms: Arevirumab-3
Target:
Research Areas:
Cat. No.: HY-169385
CAS No.: 2925060-81-5
Target:
Research Areas:
ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
Cat. No.: HY-178736S
Synonyms: DLPE-d46; 1,2-Dilauroyl-sn-glycero-3-PE-d46
Cat. No.: HY-W015954R
CAS No.: 24347-58-8
Cat. No.: HY-L018
458 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.
MCE designs a unique collection of 458 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.
Cat. No.: HY-L936V0
11412 compounds
Molecular Glue Virtual Library is constructed using generative AI technology, integrating the structural features, activity data of known molecular glues, and interaction information of ternary complexes (target protein-E3-molecular glue). Endowed with structural novelty, drug-likeness, diversity and synthesizability, it is applicable to molecular glue-based AI drug screening and large-scale virtual screening.
MCE builds this library based on high-quality molecular building blocks by virtue of robust computing power, coupled with rigorous reaction rules and optimized compound generation strategies. To ensure library quality, molecules with high synthetic difficulty, poor drug-likeness, PAINS and other undesirable molecules are excluded first. Subsequently, scaffold-based compound analysis is performed to screen drug-like diverse molecules for synthesizability evaluation; those with excessively high synthetic difficulty are removed, ultimately forming a large-scale molecular glue virtual library with structural diversity, synthesizability and drug-likeness.
Compounds in the library can be synthesized in only 1-2 chemical reaction steps. With MCE’s experienced chemical synthesis team, custom synthesis of different scales from milligram to kilogram can be easily achieved to meet diverse customer needs.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
